GeneDx Holdings Corp. shares fell over 49% after the company reported weaker-than-expected Q1 results and lowered its 2026 revenue guidance from $540-555 million to $475-490 million. The company also revealed a $31.3 million goodwill impairment related to its Fabric Genomics acquisition and disclosed lower-than-expected reimbursement rates. These developments led to a securities class action lawsuit alleging that GeneDx and its executives misled investors about the company's financial health and prospects. Investors who bought shares between April 16, 2025, and May 4, 2026, are encouraged to contact Faruqi & Faruqi LLP to discuss their legal options before the August 3, 2026 deadline to seek lead plaintiff status.
GeneDx Holdings Corp. faces a class action lawsuit alleging it misled investors about the viability of Fabric Genomics, a company it acquired. The lawsuit claims GeneDx and executives made false statements and failed to disclose problems that hurt bu...
GeneDx Holdings Corp. shares dropped 49% on May 5, 2025, after the company reported a massive tenfold increase in net loss for Q1 2026 and cut its full-year 2026 revenue guidance by 12%. The company’s average reimbursement rate fell short due to a sh...
A class action lawsuit has been filed against GeneDx Holdings Corp. and some of its officers for allegedly misleading investors between April 16, 2025, and May 4, 2026. The complaint claims the company made false statements and failed to disclose key...
GeneDx Holdings Corp. shares fell over 49% after the company reported weaker-than-expected Q1 results and lowered its 2026 revenue guidance from $540-555 million to $475-490 million. The company also revealed a $31.3 million goodwill impairment relat...
